Connect Biopharma Holdings Limited (CNTB)
The price, the headline numbers and the latest news, in one place.
Connect Biopharma Holdings Limited (CNTB) Stock Price, Analysis & Data
| Bid | 1.5 |
| Market Cap | 116M |
| Revenue (ttm) | 2.95M |
| Net Income (ttm) | -69M |
| 0.00 | |
| -1.19 | |
| n/a | |
| -2.47 | |
| P/B (ttm) | 4.31 |
| P/S (ttm) | 39.24 |
| Earnings Date | n/a |
| Ask | 2.71 |
| Volume | 2,402,594 |
| Avg. Volume (20D) | 615,553 |
| Open | 2.01 |
| Previous Close | 1.93 |
| Day's Range | 1.74 - 2.03 |
| 52-Week Range | 1.23 - 3.82 |
| Analyst | Strong<br>Buy |
| Price Target | 7 (280.43%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CNTB
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California....
Financial Performance
In 2025, Connect Biopharma s's revenue was 64K, a decrease of -99.75% compared to the previous year's 26.03M. Earnings were -55.48M, an increase of 255%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for CNTB stock is "Strong Buy". The 12-month stock price forecast is 7, which is upside of 280.43% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $2.77M misses estimates by $0, with 5666.67% YoY growth.
- EPS of -0.27 exceeds estimates by 0.04, with -42.11% YoY decline.
